Open access · CC-BY
via OpenAlex
Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease
Shichun Tu, Shu‐ichi Okamoto, Stuart A. Lipton, Huaxi Xu
Molecular Neurodegeneration · 2014 · ▲ 583 citations
Abstract
Alzheimer's disease (AD) is a devastating disease characterized by synaptic and neuronal loss in the elderly. Compelling evidence suggests that soluble amyloid-β peptide (Aβ) oligomers induce synaptic loss in AD. Aβ-induced synaptic dysfunction is dependent on overstimulation of N-methyl-D-aspartate receptors (NMDARs) resulting in aberrant activation of redox-mediated events as well as elevation of cytoplasmic Ca2+, which in turn triggers downstream pathways involving phospho-tau (p-tau), caspases, Cdk5/dynamin-related protein 1 (Drp1), calcineurin/PP2B, PP2A, Gsk-3β, Fyn, cofilin, and CaMKII and causes endocytosis of AMPA receptors (AMPARs) as well as NMDARs. Dysfunction in these pathways leads to mitochondrial dysfunction(definition), bioenergetic compromise and consequent synaptic dysfunction and loss, impaired long-term potentiation (LTP), and cognitive decline. Evidence also suggests that Aβ may, at least in part, mediate these events by causing an aberrant rise in extrasynaptic glutamate levels by inhibiting glutamate uptake or triggering glutamate release from glial cells. Consequent extrasynaptic NMDAR (eNMDAR) overstimulation then results in synaptic dysfunction via the aforementioned pathways. Consistent with this model of Aβ-induced synaptic loss, Aβ synaptic toxicity can be partially ameliorated by the NMDAR antagonists (such as memantine and NitroMemantine). PSD-95, an important scaffolding protein that regulates synaptic distribution and activity of both NMDA and AMPA receptors, is also functionally disrupted by Aβ. PSD-95 dysregulation is likely an important intermediate step in the pathological cascade of events caused by Aβ. In summary, Aβ-induced synaptic dysfunction is a complicated process involving multiple pathways, components and biological events, and their underlying mechanisms, albeit as yet incompletely understood, may offer hope for new therapeutic avenues.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/1750-1326-9-48
- Canonical
- link ↗
- Fetched
- 2026-09-29 MST
Cite this
APA
Tu, S., Okamoto, S., Lipton, S.A., & Xu, H. (2014). Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease. <em>Molecular Neurodegeneration</em>. https://doi.org/10.1186/1750-1326-9-48
Vancouver
Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease. Molecular Neurodegeneration. 2014. doi:10.1186/1750-1326-9-48.
BibTeX
@article{shichun2014Oligom,
title = {Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease},
author = {Shichun Tu and Shu‐ichi Okamoto and Stuart A. Lipton and Huaxi Xu},
journal = {Molecular Neurodegeneration},
year = {2014},
doi = {10.1186/1750-1326-9-48},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Human Molecular Genetics 2010
Open access · OA
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Molecular neurobiology 2026
Citation only
The Interplay of Metabolic Dysfunction, Neuroinflammation, and Mitochondrial Dysfunction in Balance Impairment: Insights from Type 2 Diabetes Mellitus and Alzheimer's Disease.
Pharmaceuticals 2021
Open access · CC-BY
Nrf2/ARE Activators Improve Memory in Aged Mice via Maintaining of Mitochondrial Quality Control of Brain and the Modulation of Gut Microbiome
Molecular Cancer 2023
Open access · OA
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments
The World Journal of Men s Health 2022
Open access · CC-BY
The Role of Mitochondrial Dynamic Dysfunction in Age-Associated Type 2 Diabetes
Aging 2020
Preprint · CC-BY